Items with tag "antibodies"

News

V-Bio Ventures leads Camel-IDS EUR 37m Series A financing

15 November 2018, Ghent (Belgium) - V-Bio Ventures leads Camel-IDS EUR 37m Series A financing to develop cancer targeted radiopharmaceuticals Camel-IDS is developing new radiopharm…

Read more

Confo Therapeutics is awarded a EUR 1M grant to increase its screening capabilities

Confo Therapeutics announced today that it has received a €1 million grant from the Flemish Government through Flanders Innovation & Entrepreneurship (VLAIO). The grant will be used to support the…

Read more

Sanofi acquires Ablynx for €3.9 billion

Sanofi and Ablynx entered into a definitive agreement under which Sanofi will offer to acquire all of the outstanding ordinary shares, including shares represented by American Depositary Shares (A…

Read more

Ablynx' caplacizumab receives fast track designation from FDA

The fast track designation would allow caplacuzimab to enter the market 6 to 10 months earlier

Read more

ABLYNX APPOINTS MARKUS EWERT AS CHIEF BUSINESS OFFICER

Ablynx today announced the appointment of Markus L.E. Ewert, PhD, MBA, as Chief Business Officer (CBO). Effective from 20 June 2017, Dr Ewert will lead the Company's business development and corpo…

Read more

argenx raises $100 million with NASDAQ IPO

With its Nasdaq debut, argenx raises $100 million, a significantly greater amount than the $60 million previously planned.

Read more

Ablynx finishes preclinical work on osteoarthritis nanobody for Merck

The first nanobody from the Ablynx-Merck collaboration reaches clinical development, triggering a €15m milestone payment to Ablynx.

Read more

argenx receives first preclinical milestone payment in AbbVie collaboration

ARGX-115, an antibody targeting to inhibit the release of TGF-beta from regulatory T-cells in an innovative way, reaches its first preclinical milestone. This triggers a $10 million payment from d…

Read more

argenx launches Phase II study for cutaneous T-cell lymphoma therapy

argenx starts a new phase II clinical trial with ARGX-110, a SIMPLE antibody targeting CD70. ARGX-110 will be evaluated as a monotherapy for relapsed/refractory cutaneous T-cell lymphoma (CTCL).

Read more

argenx and Broteio Pharma jointly develop antibodies for severe autoimmune diseases

argenx announces its new collaboration with Broteio Pharma. Broteio will perform preclinical research using argenx' SIMPLE antibody platform after which argenx has the exclusive option to license …

Read more

Merck releases compelling data on Ablynx-developed psoriasis nanobody

Data from a phase Ib study reveal the Ablynx-developed bi-specific nanobody targeted against IL-17A/F as a promising new therapy to treat psoriasis. Patients in the highest dose group achieved 90%…

Read more

Staten Biotech exercises option to develop argenx antibody for dyslipidemia

Ghent-based antibody developer argenx has announced that Staten Biotech has exercised its exclusive option to license ARGX-116, an anti-ApoC3 SIMPLE AntibodyTM with therapeutic potential in dyslip…

Read more

Argenx files for U.S. stock listing

argenx, the llama antibodies developer looking to treat severe autoimmune diseases and cancer, announced today that it has confidentially submitted a draft registration statement on Form F-1 to th…

Read more

argenx announces extension of therapeutic antibody alliance with Shire

Llama antibody developer for immune diseases and cancer argenx has announced the extension of its strategic partnership with Shire plc to advance the discovery and development of novel human thera…

Read more

Scientists isolate new antibodies to fight RSV

Researchers from VIB, UGent, the Geisel School of Medicine at Dartmouth and several collaborators developed a new antiviral strategy to fight human respiratory syncytial virus (RSV), a leading cau…

Read more

ABLYNX SUBMITS A MARKETING AUTHORISATION APPLICATION TO THE EUROPEAN MEDICINES AGENCY FOR CAPLACIZUMAB

In the Phase II TITAN study, treatment with caplacizumab significantly reduced the time to platelet count normalisation and the number of recurrences of aTTP while on drug treatment. Post-hoc anal…

Read more

MERCK REPORTS ENCOURAGING RESULTS WITH ABLYNX' PSORIASIS NANOBODY

• Primary objective of safety and tolerability met • In the three highest dose groups, 100% of patients achieved a 75% or greater reduction in disease activity compared to 0% for placebo • The…

Read more

argenx launches Phase II study of ARGX-113 for the treatment of myasthenia gravis

Llama antibody engineer argenx today announced the initiation of a Phase II proof-of-concept study of ARGX-113 in patients with myasthenia gravis (MG). "MG is a rare and debilitating muscle d…

Read more

John Berriman heads the Confo Therapeutics board

GPCR drug designer Confo Therapeutics has announced that John Berriman was appointed as Chairman of the Board. Berriman is a known biotech veteran and has served on the boards of many biotech comp…

Read more

Fresh money for llama biotech

Ablynx and Argen-X, two Ghent based biopharmaceutical companies, who develop drugs based on llama antibodies, easily obtained new capital from investors. ArgenX, active in the field of cancer …

Read more

Argenx attracts American investors

Ghent-based antibody producer Argenx has caught the eye of American investors. Today, Argenx announced that one of U.S.’ largest investment companies, Federated Investors, is investing 16 million …

Read more

Ablynx independently develops and markets TTP drug

Ablynx has decided to fully self-develop caplacizumab, a potential drug to treat the rare blood disease TTP. Ablynx decided to develop the nanobody caplacizumab on his own and to commercialize…

Read more

Prof. Carmeliet as Chief Scientific Strategy Advisor at Oncurious

Oncurious NV, an oncology company focused on the development of innovative medicines for the treatment of pediatric tumors, today announces the appointment of Prof Dr Peter Carmeliet as its Chief …

Read more

arGEN-x receives €1.5 million for enhancement of therapeutic antibodies

In early May 2015, arGEN-X N.V. (ARGX) received a €1.5 million grant from the Flemish IWT (the government agency for Innovation by Science and Technology). arGEN-X creates novel therapeutic antibo…

Read more

Insights

argenx signs billion-dollar deal with Janssen

argenx signs billion-dollar deal with Janssen

Another Belgian biotech on the up and up: argenx just closed a billion-dollar deal with Janssen Pharmaceutica for their antibody cusatuzumab. Under the terms of the agreement, Janssen will pay arg…

Read more

MyCartis barcodes biological samples

MyCartis barcodes biological samples

MyCartis is an early-stage company that was founded in September 2014 when Pronota (Ghent, Belgium) and the Biocartis Evalution Business unit (Lausanne, Switzerland) joined forces.  This was an id…

Read more

A guinea pig: your perfect partner to produce monoclonal antibodies

A guinea pig: your perfect partner to produce monoclonal antibodies

SynAbs is a young UCL spin-off company, founded in September 2015 with the support of Walloon life science incubator WBC, UCL’s tech transfer office LTTO and the French investment group Biotech In…

Read more

GlycoDelete: the road to plant-grown medicines

GlycoDelete: the road to plant-grown medicines

What if our pharmaceuticals could be grown in plants? It might sound like science fiction, but two VIB/UGent research groups are working hard to scrap the “fiction” part. In a recent paper publish…

Read more

SynAbs brings rats to antibody market

SynAbs brings rats to antibody market

Antibodies have become a cornerstone of modern research and in vitro diagnostics, generating yearly revenues close to 2 billion dollars. Most of these are produced in mice, despite some significan…

Read more

Nanobodies®: small magical molecules for big difficult diseases

Nanobodies®: small magical molecules for big difficult diseases

One of Belgium’s established biotech companies, Ablynx, has developed an innovative platform to produce small therapeutic proteins, called Nanobodies. These Nanobodies are being developed for the …

Read more

VC Views

Confo Therapeutics: Drugging the Undruggable

Confo Therapeutics: Drugging the Undruggable

Llama single-domain antibodies have found yet another application, one that Confo Therapeutics is fully exploiting. Ablynx is developing Nanobodies®, AgroSavfe focuses on Agrobodies®, and Confo wi…

Read more

Sign up to our Mailing List to receive updates
of our latest News, Events & Magazines

GSK XpandInnovation Flanders.bio Biowin Turnstone KU Leuven Itera Life Science Janssen UGent V-Bio Ventures

ABOUT BIOVOX - Sharing Life Sciences Innovations

BioVox showcases interesting life sciences breakthroughs for and from Belgian innovators. Through our partnership with BioCentury we share relevant worldwide innovations and business updates while our local journalists focus on regional highlights. 

Interested to get involved? Get in touch! We are looking for content, writers and partners! Blogs are available for research institutes, companies and freelance experts.

You want to reach out to the biotechnology and life sciences community, targetting selected audiences? Discover our sponsor and publication opportunities as well as tailored packages!

Contact BioVox via news@biovox.be or by completing the contact form.